Access to high cost medicines in Australia: Ethical perspectives

Australia and New Zealand Health Policy

Volumn 5, Issue , 2008, Pages

  Lu, Christine Y ^a   Macneill, Paul ^b   Williams, Ken ^c   Day, Ric ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b University of Sydney   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; GEFITINIB; IMATINIB; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRASTUZUMAB;

ARTICLE; AUSTRALIA; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SAFETY; DRUG UTILIZATION; ERYTHROCYTE SEDIMENTATION RATE; GENETIC SCREENING; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE NEED; HEALTH INSURANCE; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL ETHICS; MEDICARE; PATIENT SELECTION; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 44949144929     PISSN: 17438462     EISSN: None     Source Type: Journal    
DOI: 10.1186/1743-8462-5-4     Document Type: Article

References (33)

1. Sansom L The Australian National Medicinal Drug Policy J Quality Clinical Practice 1999, 19:31-35. 10.1046/j.1440-1762.1999.00291.x
2. Commonwealth Department of Health and Aged Care The Australian Health Care System, An Outline 2000.
3. Beauchamp TL Childress JF Justice Principles of Biomedical Ethics New York, Oxford University Press Beauchamp TL and Childress JF 5th 2001, 225-282
4. High Cost Drugs Working Party Drug and Therapeutics Committee Template for Formulary Submissions - Decision algorithm. http://www.ciap.health.nsw.gov.au/nswtag/high_cost_drugs-wp.html (cited 12 Oct 2006)
5. Australian Government Department of Health and Ageing Pharmaceutical Benefits Scheme: Outcomes of Pharmaceutical Benefits Advisory Committee meetings. http://www.aodgp.gov.au/internet/wcms/publishing.nsf/Content/ health-pbs-general-outcomes_full.htm (cited 29 Dec 2007)
6. Sansom L The subsidy of pharmaceuticals in Australia: Processes and challenges Aust Health Rev 2004, 28:194-205. 15527399
7. Australian Government Department of Health and Ageing Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners (1 August 2005) http://www.health.gov.au/pbs
8. Biller-Andorno N Lie RK ter Meulen R Evidence-based medicine as an instrument for rational health policy Health Care Anal 2002, 10:261-275. 10.1023/A:1022947707243 12769414
9. Kerridge I Lowe M Henry D Ethics and evidence based medicine BMJ 1998, 316:151-153.
10. Saarni SI Gylling HA Evidence based medicine guidelines: A solution to rationing or politics disguised as science? J Med Ethics 2004, 30:171-175. 1733818 15082812 10.1136/jme.2003.003145
11. Hope T Evidence based medicine and ethics J Med Ethics 1995, 21:259-260. 1376770 8558537
12. Morrow RH Bryant JH Health Policy Approaches to Measuring and Valuing Human Life: Conceptual and Ethical Issues Am J Public Health 1995, 85:1356-1360. 1615602 7573617
13. Berghmans R Berg M van den Burg M ter Meulen R Ethical issues of cost effectiveness analysis and guideline setting in mental health care J Med Ethics 2004, 30:146-150. 1733826 15082807 10.1136/jme.2003.007047
14. Hall WD Ward R Liauw WS Brien JE Lu CY Tailoring access to high cost, genetically targeted drugs Med J Aust 2005, 182:607-608. 15963014
15. Lu CY An examination of systems of access to important high-cost drugs: a critical analysis of the nationally subsidized scheme of access to tumour necrosis factor inhibitors in Australia School of Medical Sciences, Faculty of Medicine Sydney, University of New South Wales 2007.
16. Australian Government Department of Health and Ageing Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners (1 August 2003) http://www.health.gov.au/pbs/
17. Sansom L Subsidised access to TNFa inhibitors: Is the rationale for exclusion of rheumatoid factor negative patients defensible? [comment] Med J Aust 2004, 181:457-458. 15487967
18. Lu CY Williams KM March LM Bertouch J Day RO Lack of evidence for an association between rheumatoid factor status and clinical response in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors Intern Med J 2004, 34:A104.
19. Lu CY Williams KM March LM Bertouch J Day RO Subsidised access to TNFa inhibitors: Is the rationale for exclusion of rheumatoid factor negative patients defensible? Med J Aust 2004, 181:457. 15487967
20. Mann EL Subsidised access to TNF-alpha inhibitors: Is the rationale for exclusion of rheumatoid factor negative patients defensible? Med J Aust 2005, 182:47-48. 15651955
21. Australian Government Department of Health and Ageing Recommendations made by the Pharmaceutical Benefits Advisory Committee in March 2005. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ pbacrec-pbacrecmar05-copy2 (cited 29 Dec 2007)
22. Daniels N Accountability for reasonableness BMJ 2000, 321:1300-1301. 1119050 11090498 10.1136/bmj.321.7272.1300
23. Lu CY Williams KM Day RO March LM Sansom L Bertouch J Access to high cost drugs in Australia: Risk sharing scheme may set a new paradigm BMJ 2004, 329:415-416. 514195 15321884 10.1136/bmj.329.7463.415
24. Lu CY Ritchie J Williams KM Day RO Recent developments in targeting access to high cost medicines in Australia Aus NZ Health Policy 2005, 2:28. 10.1186/1743-8462-2-28
25. Lu CY Ritchie J Williams K Day R The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia Aus NZ Health Policy 2007, 4:26. 10.1186/1743-8462-4-26
26. Daniels N Toward ethical review of health system transformations Am J Public Health 2006, 96:447-451. 1592698 16449582 10.2105/AJPH.2005.065706
27. Lu CY Williams KM Day RO Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: Are we on target? Intern Med J 2006, 36:19-27. 10.1111/ j.1445-5994.2005.00992.x 16409309
28. Lu CY Williams K Day R The funding and use of high-cost medicines in Australia: The example of anti-rheumatic biological medicines Aus NZ Health Policy 2007, 4:2. 10.1186/1743-8462-4-2
29. Burton SL Randel L Titlow K Emanuel EJ The ethics of pharmaceutical benefit management Health Aff (Millwood) 2001, 20:150-163. 10.1377/ hlthaff.20.5.150 11558699
30. Lu CY Williams KM Day RO Accessing health outcome data on high cost medicines in Australia Med J Aust 2006, 184:411-413. 16618242
31. Australian Government Department of Health and Ageing 2002 Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee: Including major submissions involving economic analyses. http://www.healthconnect.gov.au/internet/ wcms/publishing.nsf/Content/ health-pbs-general-pubs-guidelines-index.htm1 (cited 29 Dec 2007)
32. Brown L Walker A Waters AM Harding A Thurecht L Funding of high cost biotechnology and other innovative targeted therapies under the Pharmaceutical Benefits Scheme Canberra, NATSEM 2002.
33. Harvey R Options for reforming the Pharmaceutical Benefits Scheme: Submission to the Interdepartmental Committee Sydney, Australian Council of Social Services 2002.